GlassScriptPhysician profile
Joann Colbert
NPI 1609905892
$3,319.26
in general payments reported to CMS, 2019-2025
25 companies · $997 in 2025
The $997 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $430 · 2023: $800 · 2024: $930 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652 · Gift: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.44 |
| Gift | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $464.68 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $462.97 | 2023-2025 | |
| Novo Nordisk INC | $443.74 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $309.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $276.71 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $167.47 | 2022-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $120.54 | 2022-2025 | |
| Pfizer INC. | $117.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $116.30 | 2021-2025 | Shingrix, Nucala, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $99.67 | 2023-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $87.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $77.28 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.25 | 2022-2025 | Jardiance, Spiriva Respimat |
| Sekisui Diagnostics LLC | $75.00 | 2025 | |
| Abbvie INC. | $74.68 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $61.84 | 2021 | |
| Cvrx, INC. | $48.84 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $48.36 | 2024-2025 | Farxiga, Breztri |
| Corcept Therapeutics | $47.52 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.00 | 2022-2023 | Trulance, Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $30.29 | 2024-2025 | Eliquis |
| Paratek Pharmaceuticals, INC. | $18.72 | 2025 | Nuzyra |
| Averitas Pharma INC. | $18.27 | 2024 | Qutenza |
| Modernatx, INC. | $14.96 | 2025 | Mresvia |
| Phadia US INC. | $14.69 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Colbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.